Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/215

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220202930RNA vaccine against SARS-CoV-2 variants
US 30.06.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17558257 Applicant CureVac AG Inventor Nicole ROTH

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

2.WO/2022/140706IMMUNE-REGULATORY LI-KEY PEPTIDE VACCINES FOR PROPHYLAXIS AND LONG-TERM PROTECTION AGAINST SARS-COV-2 INFECTION AND COVID-19 DISEASE
WO 30.06.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/065178 Applicant PURCELL, Richard, D. Inventor PURCELL, Richard, D.
The disclosure details methods for producing peptide-based vaccines for immunizing mammalian subjects against the SARS Coronavirus SARS-CoV-2, and additionally describes peptide vaccines and methods for immunizing mammalian subjects, including humans, to elicit a protective immune response against SARS-CoV-2 and to prevent or reduce the severity of COVID- 19 disease. Additionally, the disclosure provides methods and compositions for making and using li-Key peptide fusions with SARS-CoV-2 antigenic peptides to make immunogenic Ii-Key-SARS-CoV-2 peptide hybrid constructs exhibiting increased MHC presentation-based immune cell activation useful for vaccines against SARS-CoV-2.
3.WO/2022/139631AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY AND/OR PREVENTION OF SARS-COV-2-RELATED INFECTION
WO 30.06.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/RU2021/050447 Applicant JOINT STOCK COMPANY "BIOCAD" Inventor GERSHOVICH, Pavel Mikhailovich
The present application relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated codon-optimized nucleic acid encoding an isolated recombinant receptor-binding domain of the S glycoprotein (RBD-S) of SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2), to an expression cassette and a vector based thereon, as well as to an AAV5 (adeno-associated virus serotype 5)-based recombinant virus for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, to an AAV5-based vaccine for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, and to their use for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection.
4.WO/2022/140591BLOCKADE OF SARS-COV-2 INFECTION USING HYDROCARBON STAPLED PEPTIDES
WO 30.06.2022
Int.Class A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
Appl.No PCT/US2021/064937 Applicant THE UNIVERSITY OF CHICAGO Inventor TIAN, Yu
The disclosure is directed to methods of inhibiting coronavirus infection using a hydrocarbon stapled peptide which is a peptidomimetic of the human angiotensin-converting enzyme 2 (hACE2). The hydrocarbon stapled peptide binds to the receptor binding domain (RBD) of a coronavirus spike protein (S) and inhibits binding of the coronavirus to hACE2 expressed on the surface of host cells.
5.WO/2022/139539COMPOSITION FOR PREVENTION OR TREATMENT OF SARS-COV-2 INFECTION
WO 30.06.2022
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No PCT/KR2021/019796 Applicant AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION Inventor WOO, Hyun Goo
The present invention relates to a composition for prevention or treatment of SARS-CoV-2 infection. CSNP1, CSNP2, CSNP3, and CSNP4 bind to receptor the binding domain (RBD) of the spike protein of SARS-CoV-2 to inhibit the interaction of the spike protein of SARS-CoV-2 with ACE2, thereby interfering with the mechanism that SARS-CoV-2 enters cells or evades immunity. Thus, a composition comprising CSNP1, CSNP2, CSNP3, or CSNP4 as an active ingredient is provided as a pharmaceutical agent for prevention or treatment of SARS-CoV-2 infection (COVID19).
6.WO/2022/135563METHOD FOR SIMULTANEOUSLY INDUCING IMMUNE RESPONSE AGAINST MULTIPLE VIRUSES
WO 30.06.2022
Int.Class C07K 14/11
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
11Orthomyxoviridae, e.g. influenza virus
Appl.No PCT/CN2021/141198 Applicant SHANGHAI PUBLIC HEALTH CLINICAL CENTER Inventor XU, Jianqing
Provided is a method for simultaneously inducing an immune response against multiple viruses (such as influenza viruses and novel coronavirus). Provided is an immunogenic peptide including: (a) an immunogenic stem including an HA2 region of influenza virus hemagglutinin HA; (b) an immunogenic crown including a viral membrane protein or an immunogenic fragment thereof; and (c) optionally, other portions fused to the above-mentioned portions, wherein the virus from which the viral membrane protein is derived is different from the virus from which the HA2 region in (a) is derived.
7.WO/2022/136628METHOD FOR DETERMINING WHETHER AN IMMUNE RESPONSE HAS OCCURRED IN SUBJECTS WHO HAVE BEEN INFECTED WITH- OR VACCINATED AGAINST CORONAVIRUS
WO 30.06.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2021/087460 Applicant DERMOCOVID LLC Inventor SERRANO, Julián Alberto
The present invention refers to the medical field. Particularly, it refers to a method for determining whether an immune response has occurred in subjects who have been infected with- or vaccinated against coronavirus.
8.20220202932COMPOSITIONS AND METHODS FOR ORGAN-PROTECTIVE EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDS
US 30.06.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17689908 Applicant Combined Therapeutics, Inc. Inventor Romain Micol

Compositions are provided comprising messenger RNA constructs having at least one open reading frame (ORF), wherein the ORF is operatively linked to at least one untranslated region (UTR), wherein the UTR comprises at least one organ protection sequence (OPS), wherein the OPS sequence comprises at least a first, a second and a third micro-RNA (miRNA) target sequence, and wherein each of the at least a first, second and third the miRNA target sequences are optimised to hybridise with a corresponding miRNA sequence. The compositions and molecules provided are useful in therapies such as for the treatment of cancer, in immunotherapies, and in vaccines.

9.WO/2022/137133RNA VACCINE AGAINST SARS-COV-2 VARIANTS
WO 30.06.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/IB2021/062127 Applicant CUREVAC AG Inventor ROTH, Nicole
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID- 19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
10.WO/2022/135993PHARMACEUTICAL COMPOSITION COMPRISING LIPID-BASED CARRIERS ENCAPSULATING RNA FOR MULTIDOSE ADMINISTRATION
WO 30.06.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2021/085439 Applicant CUREVAC AG Inventor SONNTAG, Michael
The invention is inter alia directed to a pharmaceutical composition or vacdne for multidose administration comprising lipid-based carriers encapsulating an RNA, wherein the composition comprises at least one antimicrobial preservative selected from an aromatic alcohol, a sugar alcohol, thiomersal, or a combination thereof. The present invention is also directed to a kit or kit of parts for preparing and/or administering the pharmaceutical composition or vaccine for multidose administration. Also provided are methods of treating or preventing a disorders or a diseases, and first and second medical uses of the pharmaceutical composition or vacdne. Further provided is the use of aromatic alcohols, sugar alcohols, and/or thiomersal for preserving and/or preparing a composition or vaccine comprising lipid-based carriers encapsulating an RNA.